Open $114.50
Day Range 106.75 - 116.68
52 Week Range 106.75 - 188.14
Market Cap $5.14B
Shares Outstanding 34.78M
Public Float 34.05M
Beta 1.08
Rev. per Employee $429.48K
P/E Ratio N/A
EPS -$1.97
Yield N/A
Dividend N/A
Ex-Dividend Date N/A
Short Interest 3.26M 07/15/21
% of Float Shorted 9.57%
Average Volume 410.09K

5 Day	-27.69%
1 Month	-26.96%
3 Month	-28.63%
YTD	-35.44%
1 Year	-21.17%

Sell
Under
Hold
Over
Buy

Number of Ratings 16 Full Ratings

MarketWatch
Dow Jones

Nevro downgraded to hold from buy at Canaccord Genuity

Aug. 5, 2021 at 12:36 p.m. ET by Tomi Kilgore

Barron's

Brain, Spine Stimulation Devices Are a Post-Pandemic Winner, Says Raymond James

Jan. 19, 2021 at 11:24 a.m. ET by Barron's

Nevro price target raised to $205 from $175 at Truist Securities, stock rated buy

Jan. 6, 2021 at 9:56 a.m. ET by Tonya Garcia

Premium

Charting an October breakout, S&P 500 reclaims 3,500 mark

Oct. 12, 2020 at 12:06 p.m. ET by Michael Ashbaugh

Barron's

How a Winning Fund Gets Big Returns From Smaller Stocks

Sep. 23, 2020 at 7:30 a.m. ET by Barron's

Nevro upgraded to neutral from sell at UBS

Jun. 8, 2020 at 9:47 a.m. ET by Tomi Kilgore

Opinion

Three stocks that are ‘part of the solution’ to the coronavirus crisis

Mar. 24, 2020 at 6:51 a.m. ET by Philip van Doorn

Nevro upgraded to buy from hold at Canaccord Genuity

Feb. 26, 2020 at 10:35 a.m. ET by Tomi Kilgore

Nevro stock price target raised to $146 from $110 at SVB Leerink

Jan. 23, 2020 at 7:57 a.m. ET by Tomi Kilgore

Nevro started at buy with $132 stock price target at SunTrust RH

Jan. 8, 2020 at 10:07 a.m. ET by Tomi Kilgore

Nevro downgraded to perform from outperform at Oppenheimer

Jan. 6, 2020 at 7:58 a.m. ET by Tomi Kilgore

Bullish momentum persists, S&P 500 sustains break to uncharted territory

Nov. 19, 2019 at 1:02 p.m. ET by Michael Ashbaugh

Premium

Bullish momentum persists, S&P 500 sustains break to uncharted territory

Nov. 19, 2019 at 12:17 p.m. ET by Michael Ashbaugh

Premium

Charting a bull-flag breakout, S&P 500 knifes within view of record high (3,028)

Sep. 12, 2019 at 11:48 a.m. ET by Michael Ashbaugh

Nevro upgraded to overweight from underweight at Morgan Stanley

Mar. 21, 2019 at 9:42 a.m. ET by Tomi Kilgore

Premium

Charting a persistent rally attempt, S&P 500 nails major resistance

Jan. 17, 2019 at 11:44 a.m. ET by Michael Ashbaugh

Nevro's stock tumbles toward 3-year low after downbeat outlook prompts J.P. Morgan downgrade

Nov. 6, 2018 at 11:21 a.m. ET by Tomi Kilgore

Nevro stock price target cut to $63 from $80 at Canaccord Genuity

Nov. 6, 2018 at 10:30 a.m. ET by Tomi Kilgore

Nevro stock price target cut to $65 from $78 at Leerink

Nov. 6, 2018 at 7:41 a.m. ET by Tomi Kilgore

Nevro stock price target cut to $45 from $77 at J.P. Morgan

Nov. 6, 2018 at 7:35 a.m. ET by Tomi Kilgore

No Headlines Available

Other News
Press Releases

William Blair Downgrades Nevro Crop (NVRO) to Hold

Aug. 5, 2021 at 8:33 a.m. ET on TipRanks.com

Nevro Crop (NVRO) was Downgraded to a Hold Rating at Canaccord Genuity

Aug. 5, 2021 at 8:33 a.m. ET on TipRanks.com

Nevro Crop (NVRO) was Downgraded to a Hold Rating at Piper Sandler

Aug. 5, 2021 at 8:32 a.m. ET on TipRanks.com

Leerink Partners Keeps a Buy Rating on Nevro Crop (NVRO)

Aug. 5, 2021 at 8:32 a.m. ET on TipRanks.com

Nevro Corp (NVRO) Q2 2021 Earnings Call Transcript

Aug. 5, 2021 at 4:01 a.m. ET on Motley Fool

Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates

Aug. 4, 2021 at 6:25 p.m. ET on Zacks.com

What's in Store for Fulgent Genetics (FLGT) in Q2 Earnings?

Aug. 3, 2021 at 10:35 a.m. ET on Zacks.com

Nevro (NVRO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Jul. 28, 2021 at 3:03 p.m. ET on Zacks.com

Oppenheimer Remains a Hold on Nevro Crop (NVRO)

Jul. 23, 2021 at 10:55 a.m. ET on TipRanks.com

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Nevro Crop (NVRO) and HTG Molecular Diagnostics (HTGM)

Jul. 22, 2021 at 1:00 p.m. ET on TipRanks.com

Nevro's (NVRO) Senza System Approved by FDA for PDN Treatment

Jul. 21, 2021 at 10:40 a.m. ET on Zacks.com

Nevro (NVRO) Reports Impressive Preliminary Q2 Revenues

Jul. 21, 2021 at 9:32 a.m. ET on Zacks.com

Why Is Nevro (NVRO) Down 6.3% Since Last Earnings Report?

Jun. 4, 2021 at 11:31 a.m. ET on Zacks.com

Analysts Offer Insights on Healthcare Companies: and Nevro Crop (NVRO)

Jun. 3, 2021 at 5:01 a.m. ET on SmarterAnalyst

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

May. 13, 2021 at 2:03 p.m. ET on Zacks.com

Nevro (NVRO) Stock Slips 2.9% Despite Narrower Loss in Q1

May. 7, 2021 at 11:55 a.m. ET on Zacks.com

Nevro Crop (NVRO) Gets a Hold Rating from Oppenheimer

May. 6, 2021 at 10:27 a.m. ET on SmarterAnalyst

Canaccord Genuity Maintains a Buy Rating on Nevro Crop (NVRO)

May. 6, 2021 at 6:27 a.m. ET on SmarterAnalyst

Nevro Corp (NVRO) Q1 2021 Earnings Call Transcript

May. 6, 2021 at 1:31 a.m. ET on Motley Fool

Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates

May. 5, 2021 at 6:15 p.m. ET on Zacks.com

No Headlines Available

Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.